Following a protracted regulatory review, the European Medicines Agency is at last due to decide whether to recommend in favor of pan-EU marketing authorization for lecanemab, Eisai/Biogen’s disease modifying treatment (DMT) for early Alzheimer’s disease.
Lecanemab, which is approved as Leqembi in the US, Japan and in other countries, is among 15 new drugs listed as being up for an approval opinion on the